Document is current
Any future updates will be listed below
-
Authors
Corti, Giorgio
Buzo, Kristi https://orcid.org/0000-0001-8195-5260
Berrino, Enrico
Miotto, Martina
Aquilano, Maria Costanza
Lentini, Marilena
Bellomo, Sara Erika
Lorenzato, Annalisa
Bartolini, Alice
Mauri, Gianluca
Lazzari, Luca https://orcid.org/0000-0001-6841-4240
Russo, Mariangela
Di Nicolantonio, Federica https://orcid.org/0000-0001-9618-2010
Siena, Salvatore https://orcid.org/0000-0002-2681-2846
Marsoni, Silvia
Marchiò, Caterina https://orcid.org/0000-0003-2024-6131
Bardelli, Alberto
Arena, Sabrina https://orcid.org/0000-0002-1318-2494
- License Information
-
More Information
Article History
Received: 4 March 2024
Accepted: 9 September 2024
First Online: 14 October 2024
Competing interests
: S.A. reports personal fees from MSD Italia and a patent (international PCT patent application no. WO 2023/199255 and Italian patent application No. 102022000007535) outside the submitted work. C.M. reports personal consultancy fees from Roche, Bayer, AstraZeneca, Daiichi Sankyo, and Novartis outside the scope of the present work. C.M. also reports speaker fees from Veracyte and Daiichi Sankyo. A.B. declares the following competing financial interests: receipt of grants/research supports from Neophore, AstraZeneca, Boehringer; receipt of honoraria or consultation fees from Guardant Health; stock shareholder: Neophore, Kither Biotech; member of the SAB of Neophore. S.S. is an advisory board member for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi Sankyo, Guardant Health, Merck, Novartis, Roche-Genentech, and Seagen. G.M. received honoraria from COR2ED.
